5 November 2018
UCLB spinout Orchard Therapeutics, a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies, today announced the closing of its initial public offering of 16,103,572 American Depositary Shares (“ADSs”), each representing an ordinary share at an initial public offering price of $14.00 per share. The gross proceeds from the offering were $225.5 million before deducting underwriting commissions and estimated offering expenses.
Orchard Therapeutics was founded in 2015, based on research arising from the groups of Prof. Bobby Gaspar and Prof. Adrian Thrasher, at the UCL Institute of Child Health.
Read more from this story here: Orchard Therapeutics